Single Psilocybin Dose Shows Months-Long Depression Relief In Small Trial
A single dose of the psychedelic compound psilocybin reduced symptoms of depression within days and maintained benefits for more than three months in a small clinical trial. The findings, published in JAMA Network Open, add further evidence that psilocybin-assisted therapy may become a future treatment option for major depressive disorder.
The study, conducted by researchers at Sweden’s Karolinska Institutet, included 35 adults with recurrent major depressive disorder. Unlike many earlier studies, participants were not limited to treatment-resistant depression, making the results potentially more relevant to patients commonly seen in primary and specialist care.
How the Trial Was Designed
Participants were randomly assigned to receive either a single oral dose of psilocybin or an active placebo, vitamin B3 (niacin), which was intended to mimic certain physical sensations such as facial flushing. Both groups received structured psychological support before, during, and after dosing.
The therapeutic support included preparatory sessions focused on expectations, supervised dosing sessions with therapists present, and follow-up integration meetings. This combined approach reflects the current model of psychedelic-assisted therapy, in which the psychedelic substance is considered one component of a broader therapeutic process.
Researchers evaluated depression severity using standardized clinical scales and self-reported measures during a six-week follow-up period, while participants continued to be monitored for one year. The researchers were particularly interested in the speed of symptom improvement and the duration of treatment effects.
Rapid and Sustained Improvements
By the eighth day after dosing, participants who received psilocybin demonstrated clear reductions in depressive symptoms compared with the placebo group. Many participants reported improved mood, increased motivation, and reduced feelings of hopelessness or emotional numbness.
At the end of the six-week primary follow-up period, more than half of the participants in the psilocybin group no longer met diagnostic criteria for major depressive disorder. In comparison, only one participant in the placebo group achieved a similar level of recovery during the same timeframe.
The treatment was generally well tolerated, although two participants in the psilocybin group experienced anxiety that persisted for several weeks after dosing. No serious physiological complications were reported, but the authors emphasized that psilocybin was administered in a carefully controlled clinical environment.
Benefits Declined Over Time
During the one-year follow-up period, the strongest benefits observed in the psilocybin group persisted for slightly more than three months based on self-reported depression outcomes. After this period, differences between the psilocybin and placebo groups gradually narrowed as more participants in the placebo group also improved.
Such a pattern is not uncommon in depression research. Symptoms may improve over time even without active treatment, particularly when participants receive regular follow-up and supportive interaction as part of a clinical trial.
During long-term follow-up, slightly more than one-third of participants in both groups began using conventional antidepressant medications, typically around four months after the study started. This likely contributed to the gradual reduction in differences between the treatment groups.
The Challenge of Blinding Psychedelic Studies
One of the main scientific challenges highlighted by the study was maintaining blinding. Despite the use of identical capsules and an active placebo, nearly all participants correctly guessed whether they had received psilocybin or niacin because of psilocybin’s distinctive psychoactive effects.
This issue is important because expectations can strongly influence treatment outcomes in mental health research. Participants experiencing intense psychedelic effects may become more optimistic about treatment success, while those experiencing minimal effects may feel disappointed or discouraged.
Previous studies have suggested that placebo groups in psilocybin trials tend to show smaller improvements than placebo groups in conventional antidepressant studies. The current trial demonstrated a similar pattern, raising the possibility that standard placebo-controlled comparisons may overestimate psilocybin’s direct biological effects.
What This Could Mean for Future Treatment
Despite these limitations, the findings add to the growing body of evidence suggesting that psilocybin-assisted therapy may provide rapid and relatively long-lasting symptom relief for some patients with depression. Unlike traditional antidepressants taken daily, this approach relies on one or several guided therapeutic sessions.
Regulatory agencies and clinicians are closely monitoring this field, as multiple larger phase 2 and phase 3 clinical trials investigating psilocybin for depression and related conditions are currently underway worldwide. Early findings from some of these larger studies have also demonstrated meaningful reductions in depressive symptoms.
However, experts emphasize that psilocybin remains an experimental treatment rather than a standard therapy. Important questions remain regarding optimal dosing, patient selection, therapist training, and the extent to which outcomes are influenced by expectancy effects and the therapeutic environment.
For now, the authors conclude that psilocybin shows promise as a rapid-acting intervention that may benefit individuals with common forms of depression, not only those with severe treatment-resistant illness. Larger and more rigorously blinded studies will be necessary to determine its future role in mental health care.
